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Acute on Chronic Liver Failure: 
Role of the Bacterial Infections
Mauro Borzio and Elena Dionigi
Abstract
Acute-on-chronic liver failure (ACLF) refers to a syndrome characterized by 
acute deterioration of liver function of a pre-existing chronic liver disease with 
increased short-term mortality at 3 months due to multiorgan failure. Definition 
of ACLF has been refined, but differences between western and eastern areas still 
exist. Diagnosis of ACLF as recommended by the EASL-CLIF consortium is based 
on the assessment of organ dysfunction. The pathogenesis of this syndrome is 
attributable to an exaggerated host response to inflammation, responsible for the 
severe haemodynamic derangement leading to multiorgan failure. ACLF is trig-
gered by precipitating events like acute hepatitis either viral, drug-induced, toxic, 
or alcoholic, variceal bleeding and sepsis. Bacterial infection is currently consid-
ered the most frequent trigger of ACLF in Western countries. Cirrhotic patients, 
particularly if decompensated are prone to develop bacterial infection because 
loss of integrity of the intestinal mucosal barrier and translocation of pathogen-
associated molecular patterns (PAMPs). Bacterial translocation may develop into 
overt infection at different sites, along with sepsis and septic shock that may lead to 
ACLF. Epidemiology of bacterial infection in cirrhosis has been changing and this 
accounts for new antibiotic regimens as empirical therapy in critically ill cirrhotic 
patients with bacterial infection. In this chapter, we will discuss on definition, 
pathogenesis, clinical aspects and therapy of bacterial infection-related ACLF.
Keywords: acute-on-chronic liver failure (ACLF), bacterial infection,  
multi-drug-resistant bacteria, cirrhosis, sepsis, septic shock
1. Introduction
Acute-on-chronic liver failure (ACLF) is a recently recognized syndrome 
characterized by acute function deterioration on an underlying liver cirrhosis or 
chronic liver disease associated with a high short-term mortality and an immense 
health care expenditure. There is a worldwide agreement that ACLF represents 
an acute deterioration of pre-existing chronic liver disease, usually triggered by a 
 precipitating event.
Although the pathogenesis of this syndrome is still under investigation, it 
seems to be largely attributable to an exaggerate host response to inflammation 
with release of circulatory proinflammatory cytokines and mediators which lead 
to hemodynamic and cellular dysfunction (cytokine storm). Bacterial infection 
represents the most important and frequent trigger cause of ACLF even though 
other trigger events like HBV reactivation or alcohol play a relevant role.
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The prognosis of this syndrome remains dismal mainly because available thera-
peutic strategies, beside OLT, are ineffective and novel approaches are still lacking.
2. Acute-on-chronic liver failure
2.1 Definition
Definition of ACLF differs worldwide [1]. Three widely used definitions of 
ACLF are currently available from different geographic areas: the definition pro-
posed by European ACLF consortium (EASL-CLIF) [2] and the North American 
Consortium (North American Consortium for the Study of End-Stage Liver Disease 
NACSELD) [3] mostly adopted in western countries and definition proposed by the 
APASL consortium (ACLF research Consortium: AARC) which is largely employed 
in eastern countries [4, 5]. All these definitions are derived from analysis of data 
obtained in large series of patients prospectively recruited in different centers 
[2, 3, 5]. These definitions share some common items such as high mortality, but 
also significant differences including precipitating events, underlying liver disease, 
diagnostic and prognostic criteria. In the western areas, bacterial infection plays the 
most important pathogenetic role [6, 7] followed by alcohol abuse [8], whereas in 
the East, both hepatitis B and alcoholic hepatitis are considered the most frequent 
precipitating events [5]. In the CANONIC study the following factors were consid-
ered as precipitating events for ACLF: infection, current alcohol drinking, acute 
reactivation of chronic viral hepatitis, gastrointestinal bleeding or a recent medi-
cal procedure like paracentesis or transjugular intrahepatic portosystemic shunt 
positioning [6]. It is important to note that others clinical conditions have joined the 
list of precipitating causes of ACLF as DILI-related injury (mainly antitubercular 
drugs, herbal medicine, anti-retroviral drugs and methotrexate) [9, 10], autoim-
mune hepatitis reactivation [11] and more recently NASH [12].
The definition of organ failures is also variable among different definitions sug-
gesting that ACLF is not the same worldwide. Moreover, ACLF can occur not only in 
association with advanced cirrhosis but, as recently reported, even in chronic liver 
disease without cirrhosis and this issue is differently addressed in ACLF definitions 
[1]. However, ACLF should be distinguished from an acute liver failure in a pre-
existing perfectly normal liver. The definition of short-term mortality is not uni-
form as well. For example, in APASL definition this time frame is settled at 28 days 
whereas in EASL definition is settled at 3 months. All these differences account for 
the difficulty in assessing the true prevalence of ACLF. In order to merge the differ-
ent ACLF definitions, the World Gastroenterology Organization (WGO) tentatively 
proposed the following one: “ACLF is a syndrome in patients with chronic liver 
disease with or without previously diagnosed cirrhosis, characterized by acute 
hepatic decompensation resulting in liver failure (jaundice and prolongation of the 
international normalized ratio or INR) and one or more extrahepatic organ failures, 
associated with increased mortality up to 3 months [13].”
According to EASL-CLIF the definition of ACLF necessitates of extrahepatic 
organ failures (renal, brain, respiratory, and circulatory systems), being the sole 
liver failure insufficient for the diagnosis [3, 5, 6]. This specification is crucial to 
avoid to classify as ACLF an acute decompensation of an end-stage liver disease. 
Unfortunately, the definition of organ failure is not homogeneous among different 
regions being the agreement only on the definition of brain failure which should 
be graded as 3–4. Main issues showing agreement/disagreement among different 
definitions of ACLF are listed in Table 1.
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APASL EASL-CLIF NACSELD
Definition Acute hepatic insult manifesting 
as jaundice (serum bilirubin 
≥5 mg/dL) and coagulopathy 
(INR ≥ 1.5 or prothrombin activity 
<40%) and complicated within 
4 weeks by ascites and/or hepatic 
encephalopathy in a patient 
with previously diagnosed or 
undiagnosed chronic liver disease 
associated with high mortality
An acute 
deterioration 
of a preexisting 
chronic liver disease 
usually related to a 
precipitating event 
and associated with 
increased mortality 
at 3 months due to 
multisystem organ 
failure
A syndrome 
characterized by 
acute deterioration in 
a patient of cirrhosis 
due to infection 
presenting with two 
or more extrahepatic 
organ failure
Definition of 
liver failure
Bilirubin≥5 mg/dL, INR ≥ 1.5 Bilirubin >12 mg/dL Not specified
Source of 
definition
Prospective cohort of 3300 patients Prospective cohort of 
1343 patients
Prospective cohort of 
507 patients
Inclusion 
criteria
Compensated cirrhosis
CLD without cirrhosis
Acute insult to liver
Cirrhosis 
(compensated or 
decompensated)
Renal failure 
(mandatory)
Presentation not 
necessarily by liver 
failure
Repeated episode of 
ACLF admitted
Cirrhosis 
(compensated or 
decompensated)
Two extrahepatic 
organ failure
Presentation not 
necessarily by liver 
failure
Repeated episode of 
ACLF admitted
Exclusion 
criteria
Prior decompensation HCC Patients with infection 
but did not require 
hospitalization
HCC Cirrhosis without 
infection
HIV
Prior OLT
Disseminated 
malignancies
Time frame 4 weeks 4–12 weeks 
(variable)
Not defined
Acute insult Hepatic Hepatic or systemic Infection
Sepsis Consequence/complication Cause/precipitant Cause/precipitant
Organ failure Hepatic first, extrahepatic 
subsequently
Systemic 
inflammation leading 
to kidney failure as 
the primary with or 
without other organ 
failure
Systemic 
inflammation leading 
to extrahepatic organ 
failure
Disease 
severity score
AARC-score CLIF-C OF MELD
NACSELD-ACLF
Syndrome 
reversibility
Yes Not described Not described
Table 1. 
Agreement/disagreement among different ACLF definition.
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In summary, the most important differences between east and west definition of 
ACLF is the time frame of syndrome recognition. The western paradigm of organ 
failure as a prerequisite for the diagnosis of ACLF delays de facto of 7–14 days the 
presentation/diagnosis of the syndrome as compared to the eastern paradigm which 
indeed put the acute hepatic insult and liver failure as the starting point. According 
to AACR consortium, organ failure should not be used for definition of the syn-
drome, but only for prognostication [14].
2.2 Pathogenesis of ACLF
AS previously stated, ACLF is characterized by an excessive inflammatory 
response to different insults leading to a severe circulatory dysfunction involving sev-
eral organs and ending to multiorgan failure. Bacterial infection is a well-recognized 
cause of ACLF worldwide and it is the prevalent precipitating event according to the 
western definitions. Gut bacterial translocation is the initiating pathogenic mecha-
nism. Infection by viable bacteria can induce inflammation through two classes of 
molecules: pathogen-associated molecular patterns (PAMPs) and virulence-related 
factors [15]. Both PAMPS and virulence-related factors interact with the innate 
immunity through innate pattern recognition receptors (PRRs), and this results in 
production of several proinflammatory cytokines. If this response becomes excessive, 
the inflamed organism is exposed to a sort of “cytokine storm” responsible for tissue 
damage, which, in turn, causes the release of additional molecules: the damage-asso-
ciated molecular patterns (DAMPs) which accentuate and perpetuate inflammation 
[15]. This inflammatory cascade is the driven force leading to a full-blown ACLF.
However, not all cirrhotic patients exposed to bacterial infection will develop an 
ACLF. This would suggest that an individual susceptibility to inflammation does exist, 
the explaining mechanisms of which are still poorly understood. Furthermore, many 
patients developing ACLF do not have any identifiable precipitating event [6]. In these 
cases, it is hypothesized that ACLF might be initiated and sustained by undetected 
bacterial or fungal infection with subclinical intestinal translocation of bacterial PAMPs 
and succeeding increase of DAMP release. Targets of the “cytokine storm” are circulatory 
system, heart, lung, kidney, adrenal glands and brain [16]. The severity of dysfunction 
and the number of organ/systems involved are the main determinants of ACLF progno-
sis [13]. Circulatory dysfunction is characterized by a progressive peripheral arteriolar 
vasodilation (PAV) due to reduced vascular resistance responsible of reduced effective 
volemia and organ hypo-perfusion with consequent tissue damage. Heart failure is 
another hallmark of ACLF. Cardiac dysfunction is typically found in advanced cirrhosis 
and contributes to the reduction of effective volemia since the hyperdynamic state as a 
compensatory response to hypovolemia, becomes no longer able to compensate arterial 
vasodilation [17, 18]. By worsening of inflammation, hyper-dynamic state becomes even 
more pronounced and may shift into the so called “cirrhotic cardiomyopathy” found in 
40–50% of cirrhotic patients [19]. Damaged heart becomes no longer responsive to vaso-
active compounds and this causes further tissue damage perpetuating the vicious circle.
Renal failure is particularly frequent in ACLF. Acute kidney injury (AKI) 
defined as an increase in serum creatinine by ≥0.3 mg/dL in <48 hours or a 50% 
increase from a stable baseline within the past 3 months, occurs in about 20% of all 
hospitalized patients with cirrhosis [20]. AKI represents the most frequent organ 
failure in ACLF patients with a worse prognosis, hepatorenal syndrome type 1 being 
the most frequent prototype [21]. Hemodynamic instability and systemic inflam-
mation both concur to renal failure. AKI in ACLF is frequently associated with 
organic damage of kidney which should be ruled out as soon as possible in order to 
set the proper therapeutic approach (plasma volume expansion with albumin plus 
vasoconstriction therapy or renal replacement) [22].
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Brain failure, defined as grade 3 or 4 hepatic encephalopaty (HE), is part for the 
EASL-CLIF definition of ACLF and it is a strong prognostic predictor. In a large 
North American study, HE predicted short-term mortality independently of other 
organ failure [23, 24].
Relative adrenal insufficiency (RAI) is another complication detectable in 
almost half of cirrhotic patient with acute liver decompensation and should be 
regarded as part of multiorgan failure. It has been found to be associated with poor 
in-hospital survival, refractory shock, and renal failure [25]. In a prospective obser-
vational study, Piano et al. reported that cirrhotic patients with RAI have a high 
risk of developing sepsis, septic shock, organ failure, and death within 90 days. The 
authors concluded that RAI has similar prognostic value as non-renal organ failures 
and it should be included in the EASL-CLIF classification of ACLF [26].
2.3 Prognostic scores
The prognosis of ACLF is universally considered dismal with a mortality at 
4 weeks as high as 39%. Quantitation of short- and long-term mortality risk is of 
paramount importance to correctly planning therapeutic measures. This quantitation 
is quite difficult owing to the fact that ACLF patients differ as to precipitating events, 
grade of cirrhosis decompensation, number of organs involved and comorbidities.
Among single easily available laboratory parameters as predictors of outcome, 
lactate seems to be the most accurate one. In a cooperative European study [27] 
serum lactate on admission was directly related to the number of organs failing and 
to 28-day mortality (AUROC 0.72). In addition, both baseline lactate ≥5 mmol/L and 
12-hour lactate clearance emerged as independent predictors of 1-year mortality [27].
Multiple predictive scores have been proposed in the last few years. Classical 
scores as Child-Pugh score (CP), or the model for end-stage liver disease (MELD) 
and MELD-Na revealed to be inaccurate to correctly predict short-term mortality 
in ACLF patients. Therefore, several other multiparametric score systems have been 
proposed in the last few years, from western and eastern areas [14, 28, 29].
Recently, the EASL-CLIF consortium proposed the CLIF-SOFA score (Chronic 
Liver Failure-Sequential Organ Failure) [6] (Table 2). This score includes biochemi-
cal and clinical parameters indicative of organ function and stratifies ACLF patients 
into three grades of severity [6, 30–32]. This score was constructed over the assump-
tion, borrowed from the point of view of intensivists, that with increasing number 
of organ dysfunction or failure, the mortality would cumulatively increase. The 
CLIF-SOFAs, however, is complex, based on consensus and expert opinion rather 
than data, and did not significantly improve the prediction accuracy of other scores 
Organ system Score = 1 Score = 2 Score = 3
Liver: bilirubin (mg/dL) <6 6–12 >12
Kidney: creatinine(mg/dL) <2 2–3.5 >3.5 or renal replacement therapy
Brain: grade (West Haven) 0 1–2 3–4
Coagulation: INR <2.0 2.0 to <3.5 ≥3.5
Circulation: MAP (mmHg) ≥70 <70 Vasopressors
Respiratory (PaO2/FiO2) >300 ≤300 to > 200 ≤200
or SpO2/FiO2 >357 >214 to ≤ 357 ≤214
Column 3 defines organ failure.
Table 2. 
CLIF-C OF score and parameters to define organ failure.
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like Child-Pugh and MELD. For these reasons, in 2014 the CLIF Consortium, using 
CANONIC database, developed a simplified score named CLIF-C OF score (Organ 
Failure) derived from CLIF-SOFA one. Patients are stratified into three-point range 
and scored 6–18. This score confirmed to perform better than CP and MELD. A 
further refinement was obtained by adding to CLIF-C OF score age and white blood 
cells count. This refined version, named CLIF-C ACLF, was the result of a mathemati-
cal model constructed by logistic analysis carried out upon CANONIC database and 
validated on a validation set of ACLF patients. Patients are scored 1–100 by a bedside 
easy-to-use tool which is now available at the CLIF Consortium website: http://www.
clifconsortium.com/ [28]. Both CLIF-C OF and CLIF-C ACLF scores showed bet-
ter prognostic performance than the conventional prognostic scores [2, 28, 33]. In a 
recent retrospective study carried out on a cohort of 343 consecutive cirrhotic patients 
with ACLF diagnosed according to the EASL-CLIF definition and aimed at compar-
ing eight different prognostic scores, emerged that CLIF-SOFA and CLIF-C OF scores 
displayed the highest predictive accuracy [34]. In this study a CLIF-C OF score of 8 
or lower had a 92.0% NPV and 97.8% sensitivity, while a score of 17 or higher allowed 
for a 95.0% PPV and 99.4% specificity for the prediction of 28-day mortality.
The North American Consortium for the Study of End-Stage Liver Disease 
(NACSELD) in 2014 built a predictive score of short-term mortality named 
NACSELD-score further refined in 2018 [3]. According to NACSELD-ACLF score 
the presence of at least two organ failures such as shock, grade 3 or 4 encephalopa-
thy, renal failure requiring hemodialysis, or respiratory failure requiring mechani-
cal ventilation, accurately predicted 30-day survival. This score has been further 
validated in a population-based study on over 100,000 patients included in a large, 
North America representative database of hospital discharges (NIS). In this study, 
NACSELD-ACLF predicted survival with an area under the ROC curve 0.77 [35].
APASL consortium proposed a prognostic score named AARC with an elevated 
accuracy to predict early and late mortality (AUROC >80%) in patients with ACLF. 
Variables included in AARC score are bilirubin, INR, lactate, ascites and HE [14] 
(Table 3). According to this score patients are stratified as Grade I for a score of 5–7, 
Grade II for 8–10 and Grade III for 11–15 with 28-day mortality of 12.7, 44.5 and 
85.9%, respectively. The score also predicted well 28 and 90-day survival.
In summary, beyond which is the best available predictive score of ACLF to be 
adopted, early diagnosis and rapid prognostication are essential to positively impact 
on outcome of this severe complication.
2.4 Treatment
Treatment of ACLF demands for a multi-disciplinary approach involving hepa-
tologist, intensivist, infection control team, nutritionist and transplant team. The 
target of treatment is to cure the precipitating event on one side and liver, kidney, 
heart and brain failure and circulatory dysfunction on the other.
Points Total bilirubin HE grade PT-INR Lactate (mml/L) Creatinine
(mg/dL) (mg/dL)
1 <15 0 <1.8 <1.5 <0.7
2 15–25 I–II 1.8–2.5 1.5–2.5 0.7–1.5
3 >25 III–IV >2.5 >2.5 >1.5
Grade1: score 5–7, Grade 2: score 8–10, Grade 3: score 11–15.
Table 3. 
AACR-ACLF score.
7Acute on Chronic Liver Failure: Role of the Bacterial Infections
DOI: http://dx.doi.org/10.5772/intechopen.93440
2.4.1 Treatment of liver failure
In the setting of ACLF, liver transplant (OLT) is the only potentially curative 
option. However survival benefit shows great variability ranging from 43 to 75% 
in European series [36–38] and above 90% in Asia-Pacific regions [39]. The deci-
sion whether or not to list a patient for OLT has to cope with two relevant issues: 
urgency and futility. Urgency is motivated by the finding of around 67% mortality 
on waiting list for ACLF patients. This high rate of mortality is mainly due to sepsis, 
respiratory failure with mechanical ventilation, high vasopressor requirement and 
need of renal replacement treatment (RRT).
On the other hands futile transplants must be avoided. Indeed, post-transplant 
course in too sick patients if often characterized by severe prognosis. Many authors agree 
that OLT should not be offered when cardiac or pulmonary support is needed or there is 
rapidly progressive organ failure since, in these instances, OLT is unlike to offer survival 
benefit [40]. A recent observational study by Sundaram et al. [41] revealed that in 
patients with impairment of ACLF-3 grade score at listing to a lower grade at transplan-
tation, post-transplant mortality was significantly lower than in patients without this 
impairment (12% vs. 18%). Improvement in circulatory failure, brain failure, or removal 
from mechanical ventilation has the strongest impact on post-transplant survival. These 
data further reinforce the paradigm that early selection of good candidates for OLT 
(realistically within the first week from admission) is mandatory to avoid futility. To 
maximize survival benefit through a correct selection of good candidate to OLT, some 
algorithms have been proposed but they are still waiting an external validation [42, 43].
Besides OLT, other therapies for liver failure have been tempted in the last few 
years with discordant results. This is due, at least in part, to the different criteria 
employed to define ACLF from different geographic areas, making hard draw-
ing definite conclusions. Based on the assumption that ACLF may result from an 
exaggerated response to inflammation with high levels of circulating pro- and 
antiinflammation substances, extracorporeal depurating devices such as molecu-
lar adsorbent recirculating system (MARS) [44] and the PROMETHEUS [45] 
could have a role as a bridging therapy to OLT. Unfortunately, data on efficacy of 
these instruments are disappointing. In a meta-analysis and systematic review by 
Kiaergard et al., no benefit of MARS treatment in reducing mortality as compared 
to standard medical therapy was noted [46]. These conclusions were further 
confirmed by two recently published European randomized multicentric controlled 
trials, that is, HELIOS (for Prometheus) [45] and RELIEF trial (for MARS) [44] 
showing no benefit with these modalities on short-term transplant-free survival. 
Hence, their use is currently not recommended by international guidelines. 
Bioartificial liver (BAL) support devices such as AMC-BAL Bioreactor, HepatAssist 
device (employing porcine hepatocytes attached to collagen-coated micro carriers 
and charcoal columns) and extracorporeal liver assist device (ELAD)-C3A employ-
ing human hepatoblastoma cells provided inconsistent results on survival [47].
Thus, besides OLT, treatment of liver failure still remains largely disappointing.
An interesting issue is the use of non-selective beta-blockers in ACLF patients. 
In a retrospective study by Mookerjee et al. carried out on a subgroup of patients 
enrolled in the CANONIC study, those patients on carvedilol treatment (47%) had 
lower 28-day mortality (24% vs. 34%, p = 0.048), a less severe ACLF and a slower 
progression of ACLF during the study period than those not on NSBB. Moreover, 
patients who discontinued NSBBs (n = 78) after development of ACLF had a higher 
mortality (37% vs. 13%) [48]. These data prompted a randomized controlled trial 
by Kumar et al. [49] on carvedilol administration to ACLF patients without esopha-
geal varices and moderately increased HVPG. The authors reported that carvedilol 
leaded to improved survival and lowered the risk of developing AKI and SBP up 
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to 28 days. However, these preliminary data need to be further confirmed, before 
carvedilol can enter the medical armamentarium of hepatologists to cure ACLF.
2.4.2 Treatment of renal failure
Acute kidney injury (AKI) is the most common organ failure in patients with 
ACLF, being type1 hepatorenal syndrome (HRS1) the more severe prototype. It has 
been demonstrated that AKI complicating ACLF is more severe than AKI compli-
cating cirrhosis and lesser responsive to treatment [22]. The correct approach to 
AKI in cirrhosis has been specifically addressed in the last few years. Early diagnosis 
of AKI is crucial to adopt the correct treatment. A multidisciplinary panel of 
experts recently proposed a useful diagnostic algorithm based on serum creatinine 
(Scr) monitoring [50]. It should be remembered that serum creatinine tends to 
overestimate kidney function in cirrhotic patients. For hospitalized patients, the 
International Ascites Club suggests referring to the Scr determined in the last 
3 months as a baseline value to monitor and stage AKI while GFR assessment is 
not recommended [20]. Oliguria is a useful tool for diagnostic purposes and even 
a useful clinical parameter in determining the severity of renal dysfunction as 
well. Worsening oliguria or development of anuria should be considered as AKI 
until proven otherwise, regardless of any rise in Scr [20]. Volume expansion is the 
mainstay step for management of AKI. Albumin should be preferred over crystal-
loids owing to its oncotic and non-oncotic properties and it must be the first choice 
plasmaexpander in case of bacterial infection, suspected type-1 HRS or when the 
cause of AKI is unclear. The recommend regimen is infusion of 25% albumin 1 g/
kg day 1 followed by 20–40 g/day until renal function improves [20]. The goal of 
albumin infusion is to counteract the dramatic renal hypoperfusion and intrarenal 
vasoconstriction. Albumin plus vasoconstrictors infusion as terlipressin is the rec-
ommended combined therapy for HRS1 and it should be started as soon as possible. 
The earlier we start vasoconstrictor therapy the greater the chance of survival [51].
Renal replacement is the only reasonable approach when renal damage super-
venes. RRT is recommended in case of worsening AKI, worsening fluid overload 
despite diuretic therapy or worsening acid-base status [52]. The role of dialysis 
however, is still under evaluation and in clinical practice; it is mostly reserved to 
patients candidate for OLT [50, 53].
2.4.3 Treatment of circulatory and cardiac dysfunction
As previously outlined, circulatory dysfunction due to vascular vasodilation and 
consequent hypotension is a severe complication of ACLF. Cirrhotic patients with 
hyperdynamic and hypodynamic circulatory state have a higher risk of fatal ACLF 
[54]. It has been shown that arterial hypotension is an independent risk factor for 
ACLF development [55]. In particular, cirrhotic patients with hyperdynamic state 
as expressed by increased cardiac index, (>CI4.2 L/min/m2) have increased levels 
of circulating IL-6/8 and PCR and are at major risk to develop fatal ACLF [54]. 
Pharmacologic support including the amine infusion, inotropic substances and 
fluid administration are the recommended approach [53]. In critically ill patients, 
a mean arterial pressure of 60 mmHg or more should be the target [56]. Repeated 
serum lactate determination is the best way to monitor circulatory dysfunction and 
repeated lactate determination is more informative than the absolute value due to 
the impaired lactate clearance in patients with cirrhosis [57].
Careful attention to fluid supplementation is mandatory since, in cirrhosis, an 
aggressive fluid administration may lead to tissue edema and to an increased total 
body water retention which may adversely affect the outcome [58–62]. It is well 
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known that cirrhotic patients are particularly prone to develop extracellular edema, 
ascites and pulmonary edema as a consequence of too aggressive fluid administra-
tion. In volume depleted patients, normal 0.9% saline solution at an initial dose of 
10–20 ml/kg or balanced salt solutions such as PlasmaLyte are recommended [63, 
64]. Albumin infusion as plasmaexpander is highly recommended. The benefits of 
albumin infusion in patients with cirrhosis go beyond simple volume expansion and 
rely on its numerous biological properties [65, 66]. Albumin infusion is strongly 
recommended in three specific situations: SBP, large volume paracentesis and type-1 
HRS [67–72]. In addition, albumin infusion prevents AKI in patients with infections 
other than SBP [73, 74]. As to the amine choice, norepinephrine should be the first 
line agent being associated to fewer adverse events [75]. Vasopressin and terlipres-
sin may be used as second line agents able to achieve hemodynamic improvement 
[76–79]. Corticosteroids in critically ill patients may be beneficial in reducing vaso-
pressor doses and increasing the rate of shock reversal [25, 80, 81]. The rationale 
of corticosteroids administration lies on the relative adrenal insufficiency (RAI) 
that commonly comes along with circulatory dysfunction in critically ill cirrhotic 
patients. Corticosteroids have demonstrated a survival benefit in some [25, 82] but 
not in all studies [80, 81]. Hydrocortisone 200–300 mg/day in divided doses should 
be administered to patients partially responsive to vasopressor agents [83, 84].
2.4.4 Treatment of neurologic dysfunction
Brain dysfunction is part of multiorgan failure complicating ACLF and HE grade 
3 or 4 is required for diagnosis of ACLF according to EASL-CLIF definition. The 
correct interpretation and differential diagnosis of brain dysfunction is challeng-
ing since several conditions may be in cause. EEG changes are of limited value in 
the diagnosis of HE, even though EEG may help excluding other causes of altered 
mental status. Brain imaging could be useful to exclude other causes of altered 
mental status and, in particular, to exclude intra-cerebral hemorrhage in critically 
ill cirrhotic patients with coagulative disorders [85].
Measurement of fasting ammonia is routinely performed in clinical practice to 
differentiate HE from other conditions. Nevertheless, high ammonia levels alone 
are not recommended for diagnosis of HE since false positive results are frequent. 
West-Haven criteria (WHC) are useful for HE staging and managing [50] and 
advanced grade [3, 4] indicate those patients needing airways protection. Glasgow 
coma scale (GCS) is another simple clinical tool widely employed in HE patients 
and a threshold <8 is a useful parameter to decided airway protection [86].
Lactulose is the recommended initial therapy for HE. Other options such as 
rifaximine, LOLA, intravenous albumin, or other laxatives are currently not recom-
mended for HE treatment [50].
3.  Multidrug-resistant bacterial infections in patients with  
acute-on- chronic liver failure
3.1 Epidemiologic considerations
Cirrhotic patients are particularly prone to develop bacterial infection [87] and 
bacterial infection may trigger an ACLF in up to 50% of cases in western countries 
[3, 6, 88–90]. On the other hand, patients with ACLF are likely to develop sponta-
neous and secondary bacterial infections. [6, 88, 91]. Bacterial infections increase 
short-term mortality by 2–4 fold, [7, 91, 92] and it is the most important prognostic 
predictor of bad outcome [88, 93–95].
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Epidemiologic characteristics of bacterial infection have changed in the last decades. 
Until the 90s, Gram-negative bacteria were by far the main organisms detected in 
patients with cirrhosis and spontaneous bacterial peritonitis (SBP) and pneumonia 
were the most frequent sites of infection [9, 96–98]. In the last two decades we wit-
nessed a steady increase of gram-positive isolates. In a recent international cooperative 
study (Global Study) by Piano et al. including 1302 patients with bacterial infections 
(43% from Europe,32% from Asia and 25% from America), the prevalence of positive 
bacteria was up to 38% [100]. As to the site of infection, more recent studies, confirmed 
SBP, urinary tract infection, and pneumonia as the most frequent sites [100–107]. 
Fungal infection is an emerging problem as well, particularly in cirrhotic patients need-
ing ICU stay [108]. Noticeably, in the multi-center study of Galbois et al. [109], includ-
ing 31.251 patients in ICU for septic shock, the fungal infections were more frequent in 
cirrhotic than non-cirrhotic patients (9.9% vs. 6.3%, P < 0.05). Unfortunately, in most 
instances fungal infection is not recognized and this could cause delayed diagnosis, 
treatment failure and high mortality rates [110–112]. Thinking to prophylactic antifun-
gal treatment in severely ill patients without improvement after 48 hours of antibiotics, 
or in those in dialysis, corticosteroid treatment or carrying central devices is highly 
warranted and could also help improving the otherwise poor outcome.
Experts agree that early diagnosis is critical in determining the course of infection 
in cirrhotic patients [88, 113]. The acute phase proteins, such as C-reactive protein 
and procalcitonin, were reliable and early biomarkers for bacterial infection and are 
currently recommended as screening tools for the presence of bacterial infections 
along with routine cultural examination. Biomarkers such as galactomannan or B–D 
glucan are recommended for supporting the diagnosis of invasive fungal infection.
In the last 20 years, however, we record an increasing rate of bacterial infections 
sustained by multidrug-resistant (MDR) bacteria, and resistance to antibiotics is 
becoming a major global public health problem [114–119]. Recurrent hospitaliza-
tions, invasive procedures and repeated exposures to prophylactic or therapeutic 
antibiotics constitute known risk factors for drug-resistant organisms, in patients 
with decompensated cirrhosis [116]. According to internationally accepted defini-
tion, resistant bacteria can be divided into three different groups, depending on 
susceptibility to different class of antibiotics. Multidrug resistant bacteria (MDR) 
are isolates non-susceptible to at least one agent in three or more antimicrobial cat-
egories, extensively-drug resistant (XDR) are those non-susceptible to at least one 
agent in all but 2 or fewer antimicrobial categories and pandrug-resistant (PDR) are 
those non-susceptible to all currently available agents [120].
Data on prevalence and type of MDR derive mainly from single-center studies [89, 
90, 96–99, 114, 116–118, 121, 122] or from multicenter studies performed in specific 
countries [103] or assessing specific infections [123]. Canonic Study database repre-
sents an important source of information on the prevalence of MDR bacterial infec-
tions in cirrhosis across Europe, potential epidemiological differences among regions 
and centers, the characteristics of these infections, their impact on prognosis, risk 
factors for MDR and type and efficacy of empirical antibiotic treatment employed [6, 
107]. According to CANONIC data, prevalence of MDR bacterial infections in Europe 
varies in different countries being higher in Northern and Western Europe [107].
In the Global study [100], the overall prevalence of MDR bacterial infections 
varies among series from a minimum of 8% in Turkey to 27–46% in Italy peaking in 
Korea and India (87 and 69%, respectively). This high rate of MDR bacteria found 
in India may be, at least in part, explained by non-prescriptional access to antibiot-
ics in this country [124].
In Europe and USA, the highest prevalence of MDR is registered in nosocomial 
and health-care associated infections [91, 101, 104, 105, 117, 118, 121, 122, 125–129]. 
All these data unequivocally confirm that the rate of MDR bacterial infections has 
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increased almost 10%, in the last 10 years and it is becoming a problem of growing 
clinical relevance in decompensated cirrhosis and ACLF. As to the type of MDR, ESBL-
producing Enterobacteriaceae, VSE and MRSA are those most frequently isolated [28, 
89, 103, 122, 123, 130]. However, the type of resistant strain significantly differs across 
countries and centers [91, 100, 107]. The Canonic study revealed that ESBL and Amp-C 
producing Enterobacteriaceae were more frequently isolated in France, Italy, the UK 
and the Netherlands; VSE predominated in France and Austria and MRSA in infections 
occurring in the Netherlands, the UK and Ireland. This continuous change in isolated 
strains among countries demands to develop surveillance programs aimed at investigat-
ing the prevalence and epidemiological pattern of MDROs at each hospital [131].
XDR bacteria must be considered extremely dangerous in cirrhosis (as in other 
settings), and their prevalence is far from being negligible. In the study of Piano 
et al., the rate of XDR was 16% in Asia,4% in America and 5% in Europe [100].
The problem of multi-drug resistance is particularly evident in ACLF or acute liver 
decompensation. In a study by Fernandez et al., prevalence of overall infection and, in 
particular, of nosocomial infections (53% vs. 22%, p < 0.001) caused by MDRs (16% vs. 
3%, p = 0.01) was significantly higher in ACLF than AD [91]. In CANONIC database 
[107], ESBL-producing Escherichia coli, VSE, MRSA and ESBL-producing Klebsiella 
pneumoniae were the most frequent strands. The overall prevalence of MDR bacterial 
infections was 14.8% and 29.2% in culture-positive episodes and were more frequently 
isolated in bacteremia (28.6%), pneumonia (23.5%), and UTI (20.7%). MDR bacteria 
were also more frequently isolated in the ICU (23.8% vs. 12.2%, p = 0.005) and in noso-
comial infections (21.3% vs. 8.3% and 6.6% in CA and HCA infections, respectively, 
p < 0.001). Finally, MDRs were more prevalent in infections causing severe sepsis/shock 
(30.3% vs. 12.2%, p < 0.001) or ACLF (20.5% vs. 9.4%, p < 0.001).
3.2 Therapeutic considerations
Due to the urgency to treat suspected bacterial infection in critically ill cir-
rhotic patients before susceptibility tests are available, an empirical approach is the 
rule. Two types of empirical antibiotic strategies are usually employed: “classical” 
strategies based on third-generation cephalosporins, amoxicillin-clavulanic-acid/
cloxacillin or quinolones and “MDR covering strategies” including piperacillin-
tazobactam, carbapenems, ceftazidime/cefepime ± glycopeptides or linezolid/dap-
tomycin. The latter is generally considered when we face to healthcare-associated 
(HCA) or nosocomial infections [91, 114].
The initial empirical antibiotic therapy is considered appropriate when the 
antibiotic has activity in vitro adequate for the isolated pathogen in culture positive 
infections or when it solves the infection without need for further escalation, in 
culture-negative infections. Otherwise, the initial therapy is considered inappropri-
ate [91]. When the first-line empiric antibiotic therapy failed, patients experienced a 
higher rate of renal failure and death during hospitalization [103, 132] as confirmed 
by the study by Umgelter et al. [127] who found an association between failure of 
antibiotic first line regimen and mortality in SBP patients. Even, Fernandez et al. 
[114] reported a frequent inefficacy of the empiric antibiotic therapy in patients with 
high risk of death, especially in nosocomial infections. All these observations rein-
force the relevance of an appropriate first line antibiotic administration in ACLF [88].
3.3 Type and efficacy of first line antibiotic strategies
The emergence of multidrug-resistant (MDR) and extensively drug-resistant 
(XDR) bacteria has led to a decrease in the efficacy of classical empirical strategies 
based on the administration of third-generation cephalosporins. The resistance to 
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classical empirical antibiotic regimens is associated with a higher mortality rate, 
an increased duration of in-hospital stays and higher healthcare related costs when 
compared to infections caused by susceptible strains [89, 91, 98, 100, 117, 133, 134]. 
To date, it is recommended to treated nosocomial and HCA infections with empirical 
MDR covering strategies, whether a classical empirical approach is recommended 
for CA infections (Table 4). Empirical MDR covering strategies are usually more 
effective than empiric classical schemes in nosocomial infections (81.7% vs. 68%, 
respectively, p = 0.01) with a positive impact on short-term survival. A trend towards 
statistical significance is also observed in severe sepsis/shock (81.3% vs. 60.9%, 
p = 0.06). Inadequacy of first line antibiotic strategies increased 28-day mortality in 
both AD (33.3% vs. 7.7%, p < 0.001) and ACLF patients (50% vs. 25.8%, p = 0.002).
Thus, broad schemes covering all potential pathogens should be empirically 
used in the nosocomial setting and in severe sepsis/shock, followed by rapid 
de-escalation strategies to avoid a further spread of antibiotic resistance [88, 107, 
115, 135]. In a recent retrospective study from Germany [136] the authors evaluated 
the efficacy of different first line empirical antibiotic therapies in ACLF patients 
with SBP. From this study emerged that meropenem-daptomycin (99.5%), merope-
nem-linezolid, (98.5%) and meropenem-vancomycin (96.8%) combination scheme 
had the highest antimicrobial susceptibility rates and piperacillin/tazobactam 
had the highest antimicrobial susceptibility rates among the monotherapies/fixed 
combinations considering all of the Gram-negative and Gram-positive bacteria. 
On the contrary, classical empiric therapy based on cefotaxime or ceftriaxone 
showed a sensibility as low as 60%. Susceptibility of bacteria to these combination 
regimens positively impacted on inpatient mortality and complications. However, 
some pharmacologic and pharmacokinetic properties of these antibiotics should 
be considered when empirical MDR covering therapy has to be started. Linezolid 
achieves rapid penetration in peritoneum and rapidly reaches high concentration in 
tissue [137]. However, in patients with concomitant sepsis, it might not be the best 
option because the effect is more towards the bacteriostatic side, and thus might be 
too weak to ideally treat the bacteremia component [137]. Contrarily to linezolid, 
vancomycin has a lower tissue concentration and weak penetrability [138]. It is 
therefore should be preferred for sepsis [138]. Daptomycin has a very low concen-
tration in the peritoneal cavity (only 6% of that in serum) [139]. Thus, daptomycin 
should be the first-choice antibiotic to treat bacteremia and sepsis being safer than 
vancomycin. As to gram-negative infection, thanks to their moderate volume of dis-
tribution and excellent penetrability both piperacillin/tazobactam and meropenem 
could be used for infection of peritoneum as well as bacteremia/sepsis [140, 141].
As in other settings, there is a cogent need to evaluate new strategies for prevent-
ing the spread of antibiotic resistance in cirrhotic population. Many studies are inves-
tigating epidemiological surveillance through regular assessment of potential carriers 
of MDRs through rectal and nasal swabs during hospitalization [142, 143], rapid 
microbiological tests [144, 145] and antibiotic stewardship programs [113, 146, 147].
As previously stated, fungal infection is an emerging problem in cirrhotic 
patients, particularly in those with ACLF hospitalized in ICU. An early diagnosis of 
fungal infection and antifungal treatment is prognostically crucial and it has been 
associated with improved outcome [148]. Triazoles (fluconazole, itraconazole, 
voriconazole, and posaconazole) are the most frequently employed antifungal 
agents. However, due to reported emergence of azole resistant non-albicans spp., 
the first line treatment recommended in critically ill patients shifted toward a new 
antifungal class: the echinocandins (caspofungin, anidulafungin, and micafungin). 
Echinocandins are indeed, the recommended first-line treatment for patients with 
cirrhosis and nosocomial spontaneous fungal peritonitis. The usual intravenous 
dosing regimens for invasive candidiasis are as follows: caspofungin: loading dose 
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Type of infection Suspected MDR
Community acquired Nosocomial health-care 
associated
ESBL-P MRSA VSE VRE
SBP Cefotaxime or ceftriaxone Piperacilline/tazobactam Carbapenems/meropen em Vancomicin or 
teicoplanin
Linezolid or Daptomycin
Spontaneous 
bacteremia
Cefotaxime or ceftriaxone Piperacilline/tazobactam Carbapenems/meropen em Vancomicin or 
teicoplanin
Linezolid or Daptomycin
UTI Uncomplicated ciprofloxacin Nitrofurantoin or fosfomycin Carbapenems/meropen em Vancomicin or 
teicoplanin
Linezolid or Daptomycin
With sepsis Cefotaxime or ceftriaxone Piperacilline/tazobactam
Pneumonia Ciprofloxacin or moxifloxacin 
or
Ceftazidime Carbapenems + 
ciprofloxacin
Vancomicin or 
teicoplanin
Linezolid or Daptomycin
Cefotaxime or ceftriaxone Meropenem + ciprofloxacin
SBP, spontaneous bacterial peritonitis; UTI, urinary tract infection; ESBL-P, extended spectrum beta-lactamase producers; MRSA, methicillin-resistent Staphylococcus aureus; VSE, vancomycin susceptible; 
VRE, vancomycin resistant.
Table 4. 
Empirical antibiotic treatment of infection in cirrhosis (adapted from Allaire et al.) [150].
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70 mg, then 50 mg daily. No dose adjustement are recommended in case of moder-
ate and severe liver disease except for caspofungin (loading dose 70 mg, then 35 mg 
daily) [148, 149]. De-escalation from echinocandins to fluconazole is advised in 
those cirrhotic patients when their condition becomes stable.
4. Conclusions
Acute-on-chronic liver failure (ACLF) is a clinical independent entity captur-
ing the interest of hepatologists from the East and the West in the past 2 decades. 
Although universal definition does not exist, there is a substantial agreement that 
this syndrome should refer to liver failure, usually after an acute event, in a patient 
with chronic liver disease and characterized by an elevated short-term mortality. It 
should be distinguished from an ordinary decompensation of chronic liver disease 
and from acute liver failure of a normal liver. Although the pathophysiological 
mechanisms leading to this syndrome are only partly understood, systemic inflam-
mation seems to play a crucial role. Exaggerated inflammatory response, the so-
called “cytokine storm” is the main driving event leading to multiorgan failure. In 
most cases, bacterial infection is the initiating event of ACLF and early identifica-
tion and treatment is mandatory to stop SIRS-sepsis cascade and to prevent multi-
organ failure. An emerging clinical problem is represented by infection sustained by 
of MDR bacteria. This new epidemiologic reality has completely changed antibiotic 
strategies for empirical approach in decompensated cirrhosis. Control and preven-
tion of MDR infection widespread, in particular in the nosocomial setting, as well 
as to make available new treatment opportunities, beside OLT, to manage liver 
failure are the challenge of the near future.
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